FULGENT GENETICS, INC. Debt Securities, Available-for-sale, Realized Gain
FULGENT GENETICS, INC. (FLGT) reported Debt Securities, Available-for-sale, Realized Gain of $100.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGain · last filed 2026-07-30
- FULGENT GENETICS, INC. debt securities, available-for-sale, realized gain for the quarter ending 2026-06-30 was $100.00K.
- FULGENT GENETICS, INC. debt securities, available-for-sale, realized gain for the quarter ending 2023-09-30 was $0.00.
- FULGENT GENETICS, INC. debt securities, available-for-sale, realized gain for the quarter ending 2023-06-30 was $0.00.
- FULGENT GENETICS, INC. debt securities, available-for-sale, realized gain for fiscal 2020 was $131.00K.
| Period end | Debt Securities, Available-for-sale, Realized Gain 3 month | Debt Securities, Available-for-sale, Realized Gain 6 month | Debt Securities, Available-for-sale, Realized Gain 9 month | Debt Securities, Available-for-sale, Realized Gain 12 month |
|---|---|---|---|---|
| 2026-06-30 | $100.00K 10-Q · filed 2026-07-30 | $100.00K 10-Q · filed 2026-07-30 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-02 | $0.00 10-Q · filed 2024-08-02 | ||
| 2020-12-31 | $131.00K 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |